The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma*,**,★
Section snippets
MATERIAL AND METHODS
Protocol 97 was a prospective, randomized trial to assess dose intensity in relation to progression-free interval and survival in patients with suboptimal residual disease after primary cytoreductive surgery. In this study suboptimal disease was defined as any residual disease with a diameter >1 cm. No attempt was made to judge actual volume of disease or to measure the number of residual lesions. Location of residual disease was not a factor in allowing entry to the study, except that any
RESULTS
Between December 1986 and April 1990, 458 evaluable patients were entered on protocol 97. Patients with stage IV disease (153, 33%) were excluded from this analysis, because the amount of residual disease in the abdomen did not affect entry into the protocol. For example, a patient who had complete resection of intraabdominal disease could still be entered into this protocol on the basis of metastasis outside the abdomen. Thus residual abdominal disease may not be an accurate representation of
COMMENT
The focus of this study was to investigate the potential prognostic value of the maximum diameter of disease after primary cytoreductive surgery in a group of patients with stage III epithelial ovarian cancer, all of whom had residual diameters >1 cm after initial operation. In this analysis, we found no relationship between survival and the size of the tumor at exploration. However, the diameter of largest residual disease before chemotherapy is related to survival. Thus this study, similar to
References (12)
- et al.
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs. CHAP-5) in advanced ovarian carcinoma
Lancet
(1984) - et al.
Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan or melphalan plus Corynebacterium parvum (a Gynecology Oncology Group study)
Gynecol Oncol
(1986) - et al.
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study
Gynecol Oncol
(1992) - et al.
Cancer statistics, 1993
CA Cancer J Clin
(1993) - et al.
Epithelial ovarian cancer
- et al.
A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma
Cancer
(1986)
Cited by (0)
- *
From the Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, and Cornell University Medical College,a Johns Hopkins Oncology Center,b Gynecologic Oncology Group, Roswell Park Cancer Institute,c the Department of Obstetrics and Gynecology and the Section on Gynecologic Oncology, Comprehensive Cancer Center of Wake Forest University,d the Department of Obstetrics and Gynecology, Medical University of South Carolina,e the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine,f the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, New England Medical Center and Tufts University School of Medicine,g and the Gynecologic Oncology Service, Department of Obstetrics and Gynecology, University of California, Los Angeles, School of Medicine, Jonsson Comprehensive Cancer Center.h
- **
Reprint requests: Ms. Denise Mackey, Administrative Assistant, GOG Administrative Office, 1234 Market St., Suite 1945, Philadelphia, PA 19107.
- ★
0002-9378/94 $3.00 + 0 6/6/54162